Abstract
A 72-yr-old acromegalic man, who presented with pain in the left femur, was found to have a metastatic osteosarcoma. Only three cases describing the coexistence of acromegaly and osteosarcoma have been reported by the literature. As the patient didn’t have other risk factors for osteosarcoma, the hypothesis that accelerated rate of bone turnover caused by long-term exposure to high GH and IGF-I could act as a predisposing factor in the development of this malignant bone tumor is discussed.
Similar content being viewed by others
References
Rosenthal DI. Bone tumors. In: Goldman L, Ausiello D eds. Cecil Textbook of Medicine. 22nd ed. Philadelphia: W.B. Saunders. 2004, 1246–8.
Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin Orthop Relat Res 2002, 397: 40–52.
Patel SR. Radiation-induced sarcoma. Curr Treat Options Oncol 2000, 1: 258–61.
Hawkins MM, Wilson LMK, Burton HS, et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 1996, 88: 270–8.
Tucker MA, D’Angio GJ, Boice JD, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987, 317: 588–93.
Hadjipavlou A, Lander P, Srolovitz H, Enker IP. Malignant transformation in Paget disease of bone. Cancer 1992, 70: 2802–8.
Hansen MF, Nellissery MJ, Bhatia P. Common mechanisms of osteosarcoma and Paget’s disease. J Bone Miner Res 1999, 14 (Suppl 2): 39–44.
Grimer RJ, Cannon SR, Taminiau AM, et al. Osteosarcoma over the age of forty. Eur J Cancer 2003, 39: 157–63.
Neff JR. Sarcomas of bone. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, Mckenna WG eds. Clinical Oncology. 3rd ed. Edinburgh: Elsevier. 2004, 2471–572.
Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med 1970, 39: 1–16.
Alexander L, Appleton D, Hall R, WM Ross, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 1980, 12: 71–9.
Nabarro, JDN. Acromegaly. Clin Endocrinol (Oxf) 1987, 26: 481–512.
Bengtsson B, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1988, 223: 327–35.
Bates AS, Van’t Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993, 86: 293–9.
Orme SM, Mcnally RJQ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 1998, 83: 2730–4.
James RA, Dymock RB. Osteosarcoma associated with acromegaly: a case report. Pathology 1976, 8: 157–9.
Mortensen A, Bojsen-Moller M, Rasmussen P. Fibrous dysplasia of the skull with acromegaly and sarcomatous transformation. Two cases with a review of the literature. J Neurooncol 1989, 7: 25–9.
Melmed S. Acromegaly. N Engl J Med 1990, 322: 966–77.
Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict mortality in patients with acromegaly. J Clin Endocrinol Metab 2004, 89: 1613–7.
Melmed S. Acromegaly and cancer: Not a problem? J Clin Endocrinol Metab 2001, 86: 2929–34.
Baris D, Gridley G, Ron E, et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control 2002, 13: 395–400.
Ezzat S, Melmed S. Clinical review 18: are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab 1991, 72: 245–9.
Jenkins PJ, Fairclough PD, Richards T, et al. Acromegaly, colonic polyps and carcinoma. Clin Endocrinol (Oxf) 1997, 47: 17–22.
Jenkins PJ, Besser M. Acromegaly and cancer: a problem. J Clin Endocrinol Metab 2001, 86: 2935–41.
Tita P, Ambrosio MR, Scollo C, et al. High prevalence of differentiated thyroid carcinoma in acromegaly. Clin Endocrinol (Oxf) 2005, 63: 161–7.
Webb SM, Casanueva F, Wass JAH. Oncological complications of excess GH in acromegaly. Pituitary 2002, 5: 21–5.
Giovannucci E. Insulin-like growth factor-I and binding protein-3 and risk of cancer. Horm Res 1999, 51 (Suppl 3): 34–41.
Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997, 272: 12181–8.
Yu H, Rohan T. Role of insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000, 92: 1472–89.
Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998, 279: 563–6.
Hankinson SE, Willtt WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor 1 and risk of breast cancer. Lancet 1998, 351: 1393–6.
Ma J, Pollak M, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999, 91: 620–5.
Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-1 and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999, 91: 151–6.
Cohen P, Clemmons DR, Rosenfeld RG. Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res 2000, 10: 297–305.
Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 1999, 59: 2203–9.
DiGiovanni J, Kiguchi K, Anita F, et al. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci 2000, 97: 3455–60.
McCarty MF. Up-regulation of IGF binding protein-1 as an anti-carcinogenic strategy: relevance to caloric restriction, exercise, and insulin sensitivity. Med Hypotheses 1997, 48: 297–308.
Kari FW, Dunn SE, French JE, Barrett JC. Roles of insulin-like growth factor-1 in mediating the anti-carcinogenic effects of caloric restriction. J Nutr Health Aging 1999, 3: 92–101.
Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 2003, 35: 694–704.
Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol (Oxf) 1994, 41: 85–93.
Ohlsson C, Bengtsson B, Isaksson OG, Andreassen TT, Slootweg MC. Growth hormone and bone. Endocr Rev 1998, 19: 55–79.
Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev 2004, 25: 102–52.
Ezzat S, Melmed S, Endres D, Eyre DR, Singer FR. Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab 1993, 76: 1452–7.
Ueland T, Bollerslev J, Hansen TB, et al. Increased cortical bone content of insulin-like growth factors in acromegalic patients. J Clin Endocrinol Metab 1999, 84: 123–7.
Kappel CC, Velez-Yanguas MC, Hirschfeld S, Helman LJ. Human osteosarcoma cell lines are dependent on insulin-like growth factor-I for in vitro growth. Cancer Res 1994, 54: 2803–7.
Rodriguez-Galindo C, Poquette CA, Daw NC, Tan M, Meyer WH, Cleveland JL. Circulating concentrations of IGF-I and IGFBP-3 are not predictive of incidence or clinical behavior of pediatric osteosarcoma. Med Pediatr Oncol 2001, 36: 605–11.
Price CH. Primary bone-forming tumors and their relationship to skeletal growth. J Bone Joint Surg BR 1958, 40B: 574–93.
Slow IN, Friedman EW. Osteogenic sarcoma arising in a pre-existing fibrous dysplasia: report of case. J Oral Surg 1971, 29: 126–9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lima, G.A.B., Gomes, E.M.S., Nunes, R.C. et al. Osteosarcoma and acromegaly: A case report and review of the litereture. J Endocrinol Invest 29, 1006–1011 (2006). https://doi.org/10.1007/BF03349215
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03349215